MER3101: MAS-1 Adjuvanted Antigen-specific Immunotherapeutic for Prevention and Treatment of Type 1 Diabetes
Status:
Recruiting
Trial end date:
2023-04-04
Target enrollment:
Participant gender:
Summary
The study is a randomized, double-masked, placebo-controlled, Phase 1 dose-escalation
clinical trial. The objective of the trial is to determine if IBC adjuvanted with MAS-1 is
safe and will favor tolerogenic pathways to restore immunologic balance and reverse T1D
autoimmunity.
Phase:
Phase 1
Details
Lead Sponsor:
University of Colorado, Denver
Collaborators:
Nova Immunotherapeutics Limited The Leona M. and Harry B. Helmsley Charitable Trust